Anticoagulants, antiplatelets, and thrombolytics /

During the past decade, remarkable progress has been made in the development of newer drugs to prevent and treat thromboembolic disorders, such as oral direct anti-Xa and anti-IIa antagonists, as well as oral antiplatelet ADP antagonists with rapid onset and offset. In addition, there has been conce...

Full description

Bibliographic Details
Other Authors:	Mousa, Shaker A
Format:	Book
Language:	English
Published:	New York, NY : Humana, c2010
Edition:	2nd ed
Series:	Methods in molecular biology (Clifton, N.J.) ; v. 663 Methods in molecular biology (Clifton, N.J.) 663 Methods in molecular biology (Clifton, N.J.) v. 663 Springer protocols (Series) Springer protocols
Subjects:	Anticoagulants (Medicine) Blood platelets Fibrinolytic agents > Therapeutic use Fibrinolytic agents Heparin > Therapeutic use Thrombolytic therapy > Methodology Thrombolytic therapy > Methods Thrombolytic therapy Anticoagulants > therapeutic use Anticoagulants Blood Platelets Fibrinolytic Agents Platelet Aggregation Inhibitors > therapeutic use Thrombocytopenia > drug therapy Thrombolytic Therapy Thrombolytic Therapy > methods Fibrinolytic Agents > therapeutic use Heparin > therapeutic use Methods (Music) Methods

Internet

Stanford University

Holdings details from Stanford University
Call Number:	ISIL:US-CST QH506 .M45 V.663

Harvard University

Holdings details from Harvard University
Call Number:	QZ 170 A629 2010

Cornell University

Holdings details from Cornell University
Call Number:	RM340 .A58 2010

Princeton University